1) World Health Organization "Community management of opioid overdose" 2014 : 88 pages.
2) Prescrire Editorial Staff "Opioids and naloxone" Prescrire Int 2010 ; 19 (111) : 289.
3) "Naloxone hydrochloride". In : "Martindale The Complete Drug Reference" The Pharmaceutical Press, London. www.medicinescomplete.com accessed 20 March 2018 : 13 pages.
4) ANSM "RCP-Naloxone Mylan 0.4 mg/1 ml, solution injectable en ampoule" 19 October 2017 : 5 pages.
6) ANSM "Protocole d'utilisation therapeutique et de recueil d' informations. Nalscue 0.9 mg/0.1 ml solution pour pulverisation nasale en recipient unidose" 13 January 2017 : 68 pages.
7) ANSM "Rapport d'evaluation clinique-Nalscue" undated : 10 pages.
8) ANSM "Autorisation temporaire d'utilisation de cohorte. Resume du rapport de synthese periodique n°12. Nalscue 0.9 mg/0.1 ml, solution pour pulverisation nasale en recipient unidose" October 2017 + "Autorisation temporaire d'utilisation de cohorte. Resume du rapport de synthese periodique n°13. Nalscue 0.9 mg/0.1 ml, solution pour pulverisation nasale en recipient unidose" February 2018 : 4 pages.
10) Kelly AM et al. "Randomised trial of intranasal versus intramuscular naloxone in prehospital treatment for suspected opioid overdose" Med J Aust 2005 ; 182 (1) : 24-27.
11) European Monitoring Centre for Drugs and Drug Addiction Preventing fatal overdoses : a systematic review of the effectiveness of take-home naloxone" 2015 : 37 pages.
12) ANSM "RCP + notice-Nalscue" 28 July 2017 : 15 pages